AMGN
NASDAQAmgen Inc.
Price$349.54-29.64 (-7.82%)
2026-03-042026-06-05
News · 26 weeks129-65%
2025-12-142026-06-07
Mix9190d
- Insider56(62%)
- Other17(19%)
- SEC Filings8(9%)
- Dividends5(5%)
- Analyst3(3%)
- Leadership2(2%)
Latest news
25 items- PRAMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONSVESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment Gaps in Current Obesity and Diabetes CareTHOUSAND OAKS, Calif., June 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with cardiometabolic conditions and improving patient outcomes.The data include new Phase 3 VESALIUS-CV subgroup results for Repatha® in patients with high-risk diabetes (microvascular disease, insulin use or diabetic duration ≥10 years) and e
- PRAMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCETHOUSAND OAKS, Calif., June 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 9:20 a.m. ET on Tuesday, June 9, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, and Murdo Gordon, executive vice president of Global Markets and Policy at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found
- PRAMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA® in IgG4-RD Real-World Evidence Supports TAVNEOS® Efficacy and Safety Profile with Reduced Steroid Use in ANCA-Associated VasculitisTHOUSAND OAKS, Calif., June 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.New data from the Phase 3 MITIGATE trial of UPLIZNA® (inebilizumab) provide insights into the biology of immunoglobulin G4-related disease (IgG4-RD),1 while additional
- PRAMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCETHOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m. ET on Thursday, June 4, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, Narimon Honarpour, senior vice president of global development at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in Amgen's business given by management at
- PREmber LifeSciences announces new strategic investments boosting Series A to $27MLOS ANGELES, May 27, 2026 /PRNewswire/ -- Ember LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN) a leading global biotechnology company and TDF Ventures, a venture capital firm focused on early-stage investments in enterprise-focused technology sectors. The investments follow Ember LifeSciences' previously announced Series A financing led by Sea Court Capital and comes as the company announces full commercial availability of the Emb
- INSIDERDirector Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Holley Charles M was granted 665 shares, increasing direct ownership by 5% to 12,799 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Garland Greg C. was granted 665 shares, increasing direct ownership by 5% to 13,848 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Eckert Robert was granted 665 shares, increasing direct ownership by 3% to 26,251 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Druker Brian was granted 665 shares, increasing direct ownership by 9% to 8,391 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Drake Michael V was granted 665 shares, increasing direct ownership by 13% to 5,774 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- INSIDERDirector Austin Wanda M was granted 665 shares, increasing direct ownership by 9% to 8,018 units (SEC Form 4)4 - AMGEN INC (0000318154) (Issuer)
- SECAmgen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AMGEN INC (0000318154) (Filer)
- SECAmgen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - AMGEN INC (0000318154) (Filer)
- PRAMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITHThomas Dittrich Returning to Amgen as CFO THOUSAND OAKS, Calif., May 19, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith, who has served as the company's executive vice president and chief financial officer since 2020. The company also announced that Thomas Dittrich will return to Amgen as executive vice president on July 1 and succeed Griffith as chief financial officer effective September 1, 2026."We are grateful to Peter for his leadership and lasting impact on the company," said Robert A. Bradway, chairman and chief executive officer at Amgen. "Peter has helped position Amgen to deliver attractive long-term growth and expand our ability to serve
- SECSEC Form SCHEDULE 13G filed by Amgen Inc.SCHEDULE 13G - AMGEN INC (0000318154) (Subject)
- FDAFDA Approval for WEZLANA issued to AMGEN INCSubmission status for AMGEN INC's drug WEZLANA (SUPPL-6) with active ingredient USTEKINUMAB-AUUB has changed to 'Approval' on 05/12/2026. Application Category: BLA, Application Number: 761331, Application Classification:
- FDAFDA Approval for WEZLANA issued to AMGEN INCSubmission status for AMGEN INC's drug WEZLANA (SUPPL-6) with active ingredient USTEKINUMAB-AUUB has changed to 'Approval' on 05/12/2026. Application Category: BLA, Application Number: 761285, Application Classification:
- FDAFDA Approval for WEZLANA issued to AMGEN INCSubmission status for AMGEN INC's drug WEZLANA (SUPPL-6) with active ingredient USTEKINUMAB-AUUB has changed to 'Approval' on 05/13/2026. Application Category: BLA, Application Number: 761331, Application Classification:
- FDAFDA Approval for WEZLANA issued to AMGEN INCSubmission status for AMGEN INC's drug WEZLANA (SUPPL-6) with active ingredient USTEKINUMAB-AUUB has changed to 'Approval' on 05/13/2026. Application Category: BLA, Application Number: 761285, Application Classification:
- PRCNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense ResearchAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile) are responding to this challenge with next-generation delivery pla
AMGN FAQ
8 questionsWhat does Amgen Inc. do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic...Where does AMGN stock trade?
Amgen Inc. (AMGN) is listed on NASDAQ.What sector and industry is AMGN in?
Amgen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Amgen Inc. go public?
Amgen Inc. (AMGN) completed its IPO in 1983.Does AMGN pay a dividend?
AMGN's most recent ex-dividend date was 2026-05-15 with a cash dividend of $2.52 per share. No future ex-date is on file yet.What are analysts saying about AMGN?
Amgen Inc. has had 8 recent analyst actions on file. The most recent action was from Erste Group: Hold on 2026-05-05.What companies are similar to AMGN?
Notable peers in the same industry include AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG), PFE (Pfizer Inc.). Compare AMGN side-by-side with any of them on Quantisnow.How can I track AMGN on Quantisnow?
Quantisnow aggregates Amgen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMGN to receive live email and push alerts on every new disclosure.